Approval · Notice of Compliance 2017 · 1999
RELENZA: Notice of Compliance 2017
Issued November 2, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 2017
- Date
- November 2, 1999
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Antiviral agent
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RELENZA | 02240863 | Marketed |
Medicinal ingredients
- ZANAMIVIR 5 MG per BLD